腹腔镜下卵巢巧克力囊肿剥除术中止血法对卵巢功能的影响

目的探讨腹腔镜下卵巢巧克力囊肿剥除术中创面采用双极电凝和缝合止血方法对术后卵巢功能的影响。方法对60例腹腔镜下卵巢巧克力囊肿剥除术中创面采用双极电凝和缝合止血方法。电凝组（a组）30例,缝合组（b组）30例。所有患者术前、术后1个月（即术后第2次月经）及6个月分别抽血检测卵泡刺激素（FSH）、黄体生成素（LH）、雌二醇（E2）及阴道超声检查窦状卵泡数（Fo）以判断卵巢储备功能。结果2组病例在术后1个月表现为FSH、LH的升高,E2下降同时伴Fo的减少,且与术前比较差异有统计学意义（P〈O．05）。但术后6个月,通过对激素的测定,两种止血方法比较差异有统计学意义（P〈O．05）。结论腹腔镜下卵巢巧克力囊肿剥除术中双极电凝止血比缝合止血易造成卵巢储备功能降低,加重对卵巢功能的损伤。     

腹腔镜下全子宫切除同时行双侧输卵管切除的临床价值分析

目的：探讨腹腔镜下全子宫切除同时行双侧输卵管切除的临床价值。方法选择实施腹腔镜全子宫切除术治疗的124例子宫良性疾病患者作为此次研究对象,子宫切除同时行双侧输卵管切除62例患者为观察组,子宫切除同时保留输卵管62例患者为观察组,对比两组患者的手术情况、血清性激素水平以及术后围绝经期症状的发生情况。结果两组手术时长、术中出血量、住院时间、术后肠功能恢复情况以及术后取尿管时间比较无统计学差异（ P＞0.05）;两组除术后3个月的E2、FSH以及LH水平比较具有显著差异外（ P＜0.05）,其余各时间段比较无显著性差异（ P＞0.05）;观察组围绝经期症状发生率是14.5％,对照组围绝经期症状发生率是12.9％（8／62）,两组围绝经期症状发生率对比无显著性差异（P＜0.05）。结论腹腔镜下全子宫切除同时行双侧输卵管切除不会加快卵巢功能衰退,具有安全可行性,对于围绝经期且携带卵巢癌高危因素的女性可考虑子宫切除同时行预防性输卵管切除。     

围绝经期妇女子宫良性疾病子宫切除术同时切除双侧输卵管的临床应用

目的：研究围绝经期妇女子宫良性疾病行子宫切除术同时行双侧输卵管切除对卵巢功能的影响。方法：选取2008—01～2011—12在我院因子宫良性疾病行子宫切除患者98例,根据是否同时行双侧输卵管切除术分为观察组（50例）和对照组（48例）,分析比较两组术后3、6、12月血清性激素、盆腔包块、围绝经期症状的变化情况。结果：术后3～12月,患者卵泡刺激素（FSH）、黄体生成素（LH）水平呈升高趋势,雌二醇（E2）、孕酮（P）水平则呈下降趋势;术后3、12月,两组血清性激素水平无显著差异（P〉0．05）,术后6月观察组FSH、LH显著高于对照组（P〈0．05）,E2、P显著低于对照组（P〈0．05）;观察组B超盆腔包块发生率显著高于对照组（P〈0．05）;术后围绝经期症状发生率无显著差异（P〉0．05）。结论：子宫良性疾病行子宫切除术同时切除双侧输卵管可显著降低盆腔包块的发生率,同时对卵巢功能影响轻微。     

腹腔镜手术治疗特殊部位子宫肌瘤的疗效观察

目的探讨腹腔镜下微创手术对特殊部位子宫肌瘤患者术后康复及卵巢功能的影响。方法选择2017年10月-2019年2月收治的子宫肌瘤患者70例,按随机数表法分为对照组和观察组,每组各35例,对照组采用开腹子宫肌瘤剔除术治疗,观察组采用腹腔镜下子宫肌瘤剔除术治疗,对比两组术后康复状况、卵巢功能。结果观察组术后排气、术后排便、留置引流管和住院时间均低于对照组,差异有统计学意义(P<0.05);术后1个月,较对照组相比,观察组E2水平高,LH、FSH水平低,差异有统计学意义(P<0.05)。结论特殊部位子宫肌瘤患者采用腹腔镜下子宫肌瘤剔除术,创伤较小,术后康复较快,卵巢功能恢复较好。     

血清性激素水平变化对子宫肌瘤影响临床观察

目的：探讨血清性激素水平变化与子宫肌瘤病因的关系，以及子宫切除手术对卵巢功能的影响。方法：对子宫肌瘤23例（术前组），于术前测定血清促卵泡生成素（FSH）、黄体生成素（LH）、垂体生乳素（PRL）、孕激素（P）、雄激素（T）及雌激素（B）水平；对子宫肌瘤术后57例（术后组），于术后2年测定性激素含量；将健康育龄妇女52例作为对照组。测定3组6项性激素水平的变化。结果：子宫肌瘤术前组和对照组比较，FSH、LH、PRL、T水平变化有显著差异（P〈0．05），P、B水平变化有显著差异（P〉0．05）。术前组和术后组比较，FSH、LH、PRL、T、B水平变化有显著差异（P〈0．05），P水平变化无显著差异（P〉0．05）。术后组和对照组比较，FSH、LH、PRL、T、B水平变化无显著差异（P〈0．05），P水平变化无显著差异（P〉0．05）。结论：子宫肌瘤的发生和发展可能与雌孕激素受体及雄激素有关；子宫切除术后卵巢远期功能下降。     

子宫肌瘤剥除术和腹腔镜子宫次全切除术(LSH)对子宫肌瘤患者内分泌的影响

目的 探讨子宫肌瘤剥除术和腹腔镜子宫次全切除术(LsH)对子宫肌瘤患者内分泌状态的影响.方法 选取妇产科84例子宫肌瘤患者并随机分组,观察组42例患者行LSH治疗,对照组42例患者行子宫肌瘤剥除术治疗,观察两组患者治疗前、治疗后的内分泌状态变化并对比差异.结果 治疗前,两组E2、P、FSH、LH内分泌指标水平差异均无统计学意义(P＞0.05);治疗后6个月,观察组E2明显低于治疗前和对照组,P＜0.05差异具有统计学意义.结论 两种术式治疗子宫肌瘤均有显著疗效,子宫肌瘤剥除术相较LSH对子宫肌瘤患者内分泌影响较小,效果更佳.     

腹腔镜全子宫并双侧输卵管切除对绝经后妇女卵巢功能的影响

目的：探讨腹腔镜全子宫并双侧输卵管切除对绝经后妇女卵巢功能的影响。方法选取2011年7月—2013年7月汉中市中心医院妇科行腹腔镜全子宫切除术的绝经后子宫良性肿瘤患者145例（含19例脱落病例）作为研究对象,根据是否切除双侧输卵管分组,观察组86例切除双侧输卵管,对照组59例保留双侧输卵管,剔除脱落病例,观察组最终纳入75例,对照组最终纳入51例。记录2组手术时间、术中出血量、住院时间;随访术后24个月,对比手术前、术后3、12、24个月雌二醇（estradiol,E2）、卵泡刺激素（follicle stimulating hormone,FSH）、黄体生成素（luteinizing hormone,LH）、收缩期血流峰值流速（Vmax）、舒张末期最小血流速度（Vmin）、阻力值（resistance value,RI）、搏动指数（pulsatility index, PI）变化,并行改良更年期综合征（Kupperman）评分,记录随访24个月内输卵管病变、盆腔包块及再手术发生率。结果2组术后12、24个月E2、FSH、LH与术前比较,差异有统计学意义（P＜0.05）,术后3个月与术前比较,差异无统计学意义（P＞0.05）;观察组术后12、24个月E2显著低于对照组,FSH、LH显著高于对照组（P＜0.05）。2组术后Vmax、Vmin显著下降,RI、PI显著上升,与治疗前相比差异有统计学意义（P＜0.05）,但2组间术前及术后3、12、24个月各时间点对比,差异无统计学意义（P＞0.05）。观察组随访末期Kupperman评分显著高于对照组,差异有统计学意义（P＜0.05）。观察组术后输卵管病变、盆腔包块发生率分别为0、5.33%,显著低于对照组的19.61%、17.65%,差异有统计学意义（P＜0.05）。结论腹腔镜全子宫并双侧输卵管切除对卵巢功能有不良影响,会加重绝经后症状,但可降低术后输卵管病变、盆腔包块发生率。     

栓塞子宫动脉及供应子宫肌瘤的卵巢动脉治疗子宫肌瘤前瞻性研究

目的 观察有卵巢动脉供血的子宫肌瘤采用栓塞子宫动脉及供应子宫肌瘤的卵巢动脉的疗效及其对卵巢功能的影响.方法 用前瞻性研究方法对26例MR检查确诊有卵巢动脉供血的子宫肌瘤采用栓塞子宫动脉及供应子宫肌瘤的卵巢动脉,观察栓塞前、后不同时间卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇(E2)水平及子宫体积及肌瘤体积的变化.结果 患者术后1周至3个月FSH、LH增高,E2降低,术后6个月左右卵巢功能恢复正常,其中8例有明确的卵巢功能减退症状,但均为可逆性,无严重后果,2例继发闭经,考虑术后卵巢功能衰竭的发生与年龄有关,栓塞后子宫体积及肌瘤体积明显缩小.结论 有卵巢动脉供血的子宫肌瘤采用栓塞子宫动脉及供应子宫肌瘤的卵巢动脉,是安全和有价值的.     

探究子宫肌瘤患者行子宫全切术后对其卵巢内分泌功能的影响

目的：对子宫肌瘤患者进行子宫切除术对其卵巢内分泌功能的影响进行探讨。方法选取治疗的子宫肌瘤患者100例,以取得患者同意为前提,将其随机分为两组,即子宫肌瘤剔除组和子宫全切组,观察两组手术前后E2、LH及FSH含量。结果两组手术之前激素（ E2、LH、FSH ）含量无显著差异,无统计学意义（ t ＝2．318、2．173、3．692,P＞0．05）;术后2～4个月之后子宫肌瘤剔除组恢复正常月经量几率明显比子宫全切组高,差异显著,有统计学意义（t＝4．279,P＜0．05）。结论子宫肌瘤患者进行子宫肌瘤剔除手术能有效稳定卵巢内分泌功能,使用子宫全切术对自身卵巢内分泌有较大的影响,会对患者正常生活造成严重影响。     

子宫肌瘤不同手术方式对卵巢与性功能的影响

 目的 分析子宫肌瘤全子宫切除与次全子宫切除术对卵巢与性功能的影响。方法 选择2014-08至2016-08诊断症状性子宫肌瘤患者120例,按入院先后以信封法随机分为全子宫切除手术(全子宫组)与次全子宫切除手术(次全子宫组),各60例。两组年龄、病程、子宫大小、肌瘤数目及平均直径比较,差异无统计学意义。比较两组手术时间、术中出血量、术后肠道恢复时间、住院时间、住院费用,以及下肢静脉血栓、阴道感染率差异。分别于术前与术后3、6个月采用放射免疫法检测血清雌二醇(E₂)、促卵泡生成激素(FSH)、促黄体生成激素(LH)水平变化。于术前及术后6个月,采用女性性功能调查问卷指数对两组患者术后性功能进行评估。结果 次全子宫组手术时间、术中出血量、术后肠道恢复时间、住院时间、住院费用均少于全子宫组患者,术后下肢静脉血栓、阴道感染率也低于全子宫组,两组比较差异均有统计学意义(P＜0.05)。术后3、6个月,次全手术组血清E₂、FSH、LH水平与术前比较波动不明显,全子宫组术后3个月,血清E₂下降,FSH、LH水平轻度升高,6个月恢复正常水平,但不同时间点两组比较差异无统计学意义。全子宫手术组患者性功能评分显著低于次全子宫组,其中,以性交痛、性欲满意度、阴道润滑度指标明显降低,两组比较差异有统计学意义(P＜0.01)。结论 子宫肌瘤经腹子宫切除术对卵巢功能无明显影响,但子宫全切除术后性生活满意度较低。     

影响子宫肌瘤栓塞治疗的因素

目的观察子宫动脉栓塞术(UAE)对子宫肌瘤的治疗效果,并分析影响疗效的因素。方法46例症状性子宫肌瘤患者经超选择性插管双侧子宫动脉内注入PVA微粒栓塞治疗,术后6、9个月随访复查,观察临床症状改善,肌瘤体积变化情况,并对临床上治疗效果与多种不同的影响因素进行分析。结果UAE术后临床症状改善,尤其以子宫出血症状改善最为明显,栓塞后6个月肌瘤体积平均缩小45.6%,9个月肌瘤体积平均缩小58.4%。盆腔内血管解剖、内分泌、栓塞技术及肌瘤类型等因素影响子宫肌瘤栓塞后的疗效。结论双侧子宫动脉栓塞治疗子宫肌瘤是一种安全、有效的方法,其疗效与盆腔内血管解剖、内分泌、栓塞技术及肌瘤类型等多种因素有关。     

Outcome in patients undergoing unilateral uterine artery embolization for symptomatic fibroids

AIMS: To evaluate patients undergoing uterine artery embolization for symptomatic fibroids who, for technical reasons, underwent unilateral rather than bilateral embolization. PATIENTS: Prospective data were collected on 109 patients undergoing uterine artery embolization for symptomatic fibroids. Of these, six underwent unilateral embolization. They were followed with ultrasound or magnetic resonance imaging (MRI) at 3, 6 and 12 months. Patients' histories were reviewed and patients were asked to evaluate their symptoms at 3, 6 and 12 months on a scoring system, which scored their pre-embolization symptoms as 10. RESULTS: In one case the patient's symptoms did not change in the first 3 months. This patient underwent a second embolization procedure to occlude the non-embolized uterine artery. In four cases the patients' symptoms had begun to resolve at 3 months and by 12 months the patients no longer required any further treatment. In one case the patient passed a 10 cm fibroid per vagina 2 months post uterine artery embolization. After this the patient had a normal uterus on MRI and no further symptoms. CONCLUSION: Where planned bilateral uterine artery embolization is not possible for technical reasons and a unilateral embolization only is performed a conservative approach is indicated.     

子宫动脉栓塞对子宫腺肌病患者卵巢功能的影响

目的评价子宫动脉平阳霉素碘油乳剂栓塞对子宫腺肌病患者卵巢功能的影响。方法对33例子宫腺肌病患者用平阳霉素碘油乳剂进行子宫动脉栓塞,并检测栓塞前和栓塞后第1、3、6和12个月的患者以及45例正常体检女性(对照组)同期血中的雌二醇(E2)、卵泡刺激素(FSH)、黄体生成素(LH)和催乳素(PRL)水平,其后对两组结果作比较研究。结果栓塞前33例患者的FSH、LH、E2水平与正常对照组差异无显著性(P>0.05),而PRL水平高于正常对照组(P<0.05);栓塞术后1、3、6和12个月的患者FSH、LH、E2皆与术前无显著性差异(P>0.05),但PRL水平较栓塞前明显下降(P<0.05)。结论子宫动脉平阳霉素碘乳剂栓塞治疗子宫腺肌病并不影响患者的卵巢功能,且有利于降低患者的PRL水平。     

Uterine artery embolization for the treatment of uterine leiomyomata midterm results.

INTRODUCTION: The authors review their midterm experience with uterine artery embolization for the treatment of uterine fibroids. MATERIALS AND METHODS: Sixty patients were referred for permanent polyvinyl alcohol (PVA) foam particle uterine artery embolization during an 18-month period. Detailed clinical follow-up and ultrasound follow-up were obtained. RESULTS: Bleeding was a presenting symptom in 56 patients and pain was a presenting symptom in 47 patients. All patients underwent a technically successful embolization. One of the patients underwent unilateral embolization. Fifty-nine patients underwent bilateral embolization. Of all patients undergoing bilateral embolization, at last follow-up (mean, 16.3 months), 81% had their uterus and had moderate or better improvement in their symptoms. Ninety-two percent of these patients also had reductions in uterine and dominant fibroid volumes. Overall, the mean uterine and dominant fibroid volume reduction were 42.8% and 48.8%, respectively (mean follow-up, 10.2 months). One infectious complication that necessitated hysterectomy occurred. CONCLUSION: Uterine artery embolization for the treatment of uterine fibroids is a minimally invasive technique with low complication rates and very good clinical efficacy.     

腹腔镜下肌瘤剔除术与开腹手术对患者卵巢功能和免疫功能的影响

目的观察腹腔镜下肌瘤剔除术与开腹手术对患者卵巢功能和免疫功能的影响。方法选择2017年7月-2018年6月治疗的子宫肌瘤患者80例,应用随机数表法分为两组,均40例。对照组行开腹手术治疗,观察组行腹腔镜下子宫肌瘤剔除术治疗。观察两组手术前后卵巢功能[促卵泡生成激素(FSH)、促黄体生成激素(LH)]、免疫功能指标[CD4+、CD8+、CD4+/CD8+]。结果术前两组FSH、LH、CD4+、CD8+、CD4+/CD8+水平对比,差异无统计学意义(P>0.05);术后观察组FSH(20.40±1.48)U/L、LH(19.15±1.24)U/L、CD8+(29.10±2.63)%水平低于对照组(23.97±1.54)U/L、(22.57±1.38)U/L、(33.65±3.51)%,CD4+(31.08±4.81)%、CD4+/CD8+(1.22±0.07)水平高于对照组(24.13±3.49)%、(1.13±0.10),差异有统计学意义(P<0.05)。结论子宫肌瘤患者接受腹腔镜下肌瘤剔除术治疗是安全可行的,利于加快卵巢功能恢复,对免疫功能抑制较轻。     

Uterine artery embolization of symptomatic uterine fibroida . Initial success and short-term results

PURPOSE: To evaluate reduction in fibroid volume, the effect on clinical symptoms, adverse events and complications after percutaneous uterine artery embolization (UAE) as primary invasive treatment for symptomatic uterine fibroids. MATERIAL AND METHODS: Sixty-two patients entered the study. Indications for treatment were fibroid-induced menorrhagia, bulk symptoms, pain, and/or large fibroid size. The first 50 patients were evaluated by clinical examination and ultrasonography with measurement of fibroid volume before treament and 1, 6 and 12 months after UAE. The remaining 12 patients were followed 3 and 12 months after treatment. Embolization with microparticles was performed percutaneously in local analgesia by selective catheterization of both uterine arteries. RESULTS: A primary technical success with bilateral UAE was achieved in 60/62 (97%) of the patients. They were treated for postprocedural pain lasting up to 24 h. In 30 of the 62 patients with 6 months follow-up, the mean fibroid volume was reduced 68% 6 months after treatment. Twenty-nine (96%) of the patients experienced reduced bleeding, 21 (70%) reduced pain, and 18 (61%) reduced bulk symptoms at follow-up. CONCLUSION: UAE is a method with a high technical success rate. The treatment has good effect on fibroid volume reduction and clinical symptoms. Severe post-procedural pain occurs generally in successful bilateral embolizations, but complications and adverse events are otherwise few and minor. UAE represents a promising new method for treating uterine fibroid-related symptoms.     

Uterine Artery Anatomy Relevant to Uterine Leiomyomata Embolization

To categorize the anatomic variants of uterine arteries, and determine the incidence of menopausal symptoms where the tubo-ovarian branches were seen prior to embolization. Between July 1997 and June 2000, 257 (n = 257) uterine fibroid embolizations were performed at our institution. Arteriograms were retrospectively evaluated. Uterine arteries were classified into groups: type I (the uterine artery as first branch of the inferior gluteal artery), type II (the uterine artery as second or third branch of the inferior gluteal artery), type III (the uterine artery, the inferior gluteal and the superior gluteal arteries arising as a trifurcation), type IV (the uterine artery as first branch of the hypogastric artery), inconclusive, or not studied. Tubo-ovarian branches were recorded if visualized prior to and/or after embolization. Menopausal symptoms were recorded (n = 175 at 3 months, n = 139 at 6 months, n = 98 at 1 year, n = 22 at 2 years) using written questionnaires. Five hundred and fourteen uterine arteries (n = 514) were evaluated. There were 38% classifiable types, 23% inconclusive, and 39% not studied. Classification was as follows: type I, 45%; type II, 6%; type III, 43%; type IV, 6%. Among 256 patients, tubo-ovarian arteries were seen in 36 prior to embolization, but not afterwards. In this group, 25 patients reported transient menopausal symptoms (hot flashes, amenorrhea). Five patients did not report any menopausal symptoms. Six patients did not answer the questionnaires. Type I is the most common type of anatomy, followed by type III. The tubo-ovarian arteries may be visualized prior to and/or after embolization. The embolization was monitored to avoid embolization of the tubo-ovarian branches. Menopausal symptoms were transient all patients when the tubo-ovarian branches were seen prior to embolization.     

FEMIC (Fibromes Embolisés aux MICrosphères calibrées): Uterine Fibroid Embolization using Tris-acryl Microspheres. A French Multicenter Study

Purpose: A French multicenter registry was set up to confirm the safety and efficacy of large calibrated tris-acryl gelatin microspheres for embolization of symptomatic fibroids.Methods: Technical recommendations included embolization using large microspheres (>500 µm) with no secondary embolization agent. Postprocedural pain, clinical improvement and adverse events were prospectively evaluated during a follow-up period of at least 6 months.Results: Eighty-five women complaining of fibroid-related symptoms entered the study. In seven women, a secondary embolization agent was used in addition to microspheres. Complete resolution of menorrhagia was achieved in 84% of women at 24 months and significant uterine and fibroid volume reductions were noted after 6 months (37% and 73%, respectively). Three women experienced definitive amenorrhea (4%) and two women required hysteroscopic resection of a fibroid. Eight women were treated by hysterectomy because of treatment failure. In seven of these women, treatment failure was explained by an additional cause of symptoms including diffuse adenomyosis, endometrial hyperplasia or ovarian artery supply to the fibroids.Conclusion: Limited uterine artery embolization using large microspheres has good clinical success rate with low postprocedural pain and complications. Women can expect excellent midterm results with a high level of symptom control and significant fibroid volume reduction. Confidence in the end-point recommended here may require the experience of several cases.1;*See Appendix for list of members. Correspondene to: J.-P. Pelage; email:     

Fibroid calcification after uterine artery embolization: ultrasonographic appearance and pathology

PURPOSE: To describe the ultrasonographic (US) appearance of fibroid calcification occurring after uterine artery embolization (UAE) and discuss its etiology and pathology. MATERIALS AND METHODS: Twenty-seven of a total of 38 patients were followed up clinically and with duplex US for longer than 6 months after UAE for uterine fibroids. At US, changes in uterine size, fibroid vascularity, and morphology have been recorded. Pathologic studies were performed by one of the authors on resected specimens from a different cohort of patients, at intervals ranging from 4 months to 1 year after UAE. RESULTS: Twenty patients reported complete resolution of symptoms. In 16 of these, a reduction in fibroid volume of 70%-85% was recorded and, at US, the development of a peripheral hyperechoic rim around an increasingly hypoechoic fibroid was noted. Computed tomography in two patients revealed it to be a rim of calcium. Histologic studies in a different cohort of patients who had undergone hysterectomy at variable intervals after UAE demonstrated early aggregation of polyvinyl alcohol (PVA) particles, an intermediate giant cell inflammatory reaction, and calcification in the periphery of the infarcted fibroid at 6-12 months. CONCLUSION: Calcification is the end stage of hyaline degeneration. However, its peripheral location is unlike that of natural fibroid involution and hyaline necrosis. Pathologic studies in resected human fibroids after embolization suggest that its development is the end result of aggregation of PVA particles in peripheral fibroid arteries.     

Mid- and long-term quality-of-life assessment in patients undergoing uterine fibroid embolization

OBJECTIVE: Our objective was to assess the mid- and long-term outcomes concerning fibroid-specific and fibroid-associated quality of life in patients treated by uterine fibroid embolization. MATERIALS AND METHODS: A retrospective cohort study was performed, including consecutive patients with a minimum follow-up of 1 year. Analysis was performed by a questionnaire consisting of 49 questions about six topics: baseline characteristics, preinterventional status, diagnostic workup and treatment planning, periinterventional period and procedure-related quality of life, follow-up, and general satisfaction. RESULTS: The analysis was performed based on questionnaires from 53 (85.5%) of 62 patients. The mean follow-up was 3.0 +/- 1.0 (SD) years (range, 1.0-5.0 years). Uterine fibroid embolization led to a reduction of bleeding symptoms in 79.2% of patients (n = 48 before uterine fibroid embolization; n = 10 after uterine fibroid embolization), pain in 81.5% (n = 27; n = five, respectively), bulk-related symptoms in 78.6% (n = 14; n = three, respectively), urinary dysfunction in 60% (n = 10; n = four, respectively), sexual dysfunction in 71.4% (n = seven; n = two, respectively), fatigue in 62.5% (n = 24; n = nine, respectively), limitations in social life in 88.2% (n = 17; n = two, respectively), and a depressed mood in 89.5% (n = 19; n = two, respectively). The median impairment score for bleeding and pain decreased significantly from 6 to 0 and from 4 to 0, respectively (both p < 0.001). The general quality-of-life index increased significantly from 6 to 9 (p < 0.001). Forty-two (79.2%) patients judged the result as very satisfactory and would highly recommend uterine fibroid embolization to other patients. CONCLUSION: Uterine fibroid embolization leads to an impressive mid- and long-term improvement of all investigated physical and psychological fibroid-related and fibroid-associated symptoms and significantly improves women's health-related quality of life.